Drug intelligence / Profile preview

plazinemdor

Development stage: Phase 1
Lead developer: Novartis
Modality: Small Molecules
Administration: Oral

Overview

Plazinemdor (formerly known as CAD-9303) is a small molecule drug that acts as a positive allosteric modulator of the N-methyl-D-aspartate (NMDA) receptor. By enhancing NMDA receptor activity, it aims to address synaptic dysfunction implicated in neuropsychiatric and neurological disorders. Plazinemdor was originally developed by Cadent Therapeutics and later acquired by Novartis. Its primary indication has been for the treatment of schizophrenia, specifically targeting negative and cognitive symptoms that are inadequately addressed by current therapies[1][2][3][4]. The drug has undergone phase 1 clinical trials in both healthy volunteers and patients with schizophrenia[5].

Other names: plazinemdorCAD-9303CAD9303CAD 9303

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on plazinemdor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on plazinemdor.

Explore the full profile